about
Spontaneous Cannabinoid Receptor 2 (CB2) Expression in the Cochlea of Adult Albino Rat and Its Up-Regulation after Cisplatin TreatmentInfluence of the LILRA3 Deletion on Multiple Sclerosis Risk: Original Data and Meta-Analysis.Cannabinoids receptor type 2, CB2, expression correlates with human colon cancer progression and predicts patient survival.Pharmacogenomic study in patients with multiple sclerosis: Responders and nonresponders to IFN-β.A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells.Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes.Multiple sclerosis associates with LILRA3 deletion in Spanish patients.Mechanisms of action of cannabidiol in adoptively transferred experimental autoimmune encephalomyelitis.Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.Selective induction of cAMP phosphodiesterase PDE4B2 expression in experimental autoimmune encephalomyelitis.Metabolic syndrome contributes to renal injury mediated by hyperoxaluria in a murine model of nephrolithiasis.Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome.[Basic mechanisms of action of fingolimod in relation to multiple sclerosis].Cannabinoid Receptors, Mental Pain and Suicidal Behavior: a Systematic Review.R-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphtalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: Partial involvement of theThe cannabinoid receptor 1 gene (CNR1) and multiple sclerosis: an association study in two case-control groups from SpainIL28B polymorphisms are not associated with the response to interferon-β in multiple sclerosisRegulation of cannabinoid receptor gene expression and endocannabinoid levels in lymphocyte subsets by interferon-β: a longitudinal study in multiple sclerosis patientsImmunophenotype and Transcriptome Profile of Patients With Multiple Sclerosis Treated With Fingolimod: Setting Up a Model for Prediction of Response in a 2-Year Translational Study
P50
Q27324350-2C72F051-4B87-4734-A0CB-B9C0A96AC1E8Q30987368-09B2792B-9CF1-4E1B-A359-DC0F4DCBD162Q35238992-9DD2FB5D-0416-4EE6-A0DF-98974B4B8830Q36092690-1CC11F31-79C2-444D-B48B-C37ADFED7258Q40549559-EE5A789C-40B5-4BBA-8474-848A9E75C660Q41422799-2A4A0B4E-1FBF-44CF-9004-F5B024627C73Q43635768-DBF77876-AE67-46C8-9786-6B51B56033FFQ46312650-EFB087D5-384D-46A9-8183-CCC6009D726EQ46768353-8AF32FB3-13F3-473F-BE78-CFEB49ACD7F6Q46965350-A5455168-1E3E-42A0-B880-2691665969CCQ48281399-42AB44C1-9EEB-4D5D-8861-BBF4AADD4D07Q49922754-39A89B32-1F3A-4ABD-BB09-F4C6AFB2A540Q50949875-4521FCFB-A56D-4E47-9A42-3E7B7C0B6EF9Q52652770-6A3FE122-AC26-4AD2-884A-262731998234Q57359613-BCA8EE71-CF60-4C5E-8FFA-D5F0B3E03B4EQ82230911-86356CCC-FB44-4DF1-BF31-F2C0AAF02F7AQ84883466-D13FE613-54AE-40D3-8DA3-CA268D58EE8EQ85209692-8A93A0E4-B0A5-4E2C-8405-D2AE9635B4D4Q90842514-9FA62033-58C3-438F-9D70-AA9A2A9F6A61
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Antonio José Sánchez
@ast
Antonio José Sánchez
@en
Antonio José Sánchez
@es
Antonio José Sánchez
@nl
type
label
Antonio José Sánchez
@ast
Antonio José Sánchez
@en
Antonio José Sánchez
@es
Antonio José Sánchez
@nl
prefLabel
Antonio José Sánchez
@ast
Antonio José Sánchez
@en
Antonio José Sánchez
@es
Antonio José Sánchez
@nl
P106
P21
P31
P496
0000-0001-7168-6175